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Stem cells represent a promising source of neurons for the potential treatment of a host of neurological con-
ditions, including epilepsy. In this issue of Cell Stem Cell, Cunningham et al. (2014) use cortical GABAergic
interneuron progenitors derived from human embryonic stem cells to treat chronic temporal lobe epilepsy
in a mouse model.Epilepsy is a severe neurological disorder
defined by recurrent seizures, which are
abnormal, hypersynchronous electrical
discharges that emanate from dysfunc-
tional brain circuits. Epilepsy affects 1 in
26 Americans at some point in their life-
times and is associated with significant
morbidity and mortality as well as a host
of associated conditions such as cogni-
tive impairment and memory dysfunction.
Antiseizure medications—the mainstay
of treatment for epilepsy—are ineffective
in 30%–40% of patients, highlighting
the need for development of treatment
approaches that more specifically target
dysfunctional epileptic circuitry. In this
issue of Cell Stem Cell, Cunningham and
colleagues (Cunningham et al., 2014)
use inhibitory neurons derived from hu-
man embryonic stem cells (hESCs) to
successfully treat epilepsy and epilepsy-
associated behavioral abnormalities in a
mouse model.
Cortical GABAergic inhibitory interneu-
rons are known to derive from the em-
bryonic medial and caudal ganglionic
eminences (MGE and CGE, respectively).
Cortical interneurons exhibit broad diver-
sity, with specific subtypes defined by
their distinct anatomical locations, chem-
ical signatures, and temporal specifica-
tion. The MGE gives rise to two important
subclasses of interneuron; namely, those
defined by expression of the specific
markers parvalbumin (PV) and somato-
statin (Sst). Generally speaking, PV cells
are basket cells that target the cell body
of their synaptic partners, thereby control-
ling action potential generation, whereas
Sst-positive cells target the dendrites oftheir synaptic partners and influence den-
dritic excitability and synaptic integration.
Interneurons have multiple critical func-
tions in cortical information processing.
Dysfunction or disruption—particularly of
PV- and/or Sst-positive interneurons—is
hypothesized to be a mechanism that un-
derlies emergence of epilepsy (Goldberg
and Coulter, 2013).
Cunningham and colleagues have opti-
mized a protocol for generating MGE
neuronal precursors from hESCs. When
injected into the host brain of chronically
epileptic NOD SCID mice, these cells
were shown to engraft, migrate, and inte-
grate into existing cortical circuits—all
important prerequisites for the applica-
tion of this technology to the treatment
of neurological disease. The authors
found that injected neurons could
migrate >1 mm from their injection site
at 4 months, at which point most cells ex-
pressed GABA and some had expressed
markers of maturing interneurons such
as PV or Sst. Targeted whole-cell patch-
clamp recordings indicated that most
cells fired repetitive trains of action po-
tentials, although some cells displayed
immature electrophysiological parame-
ters. The grafted cells received functional
excitatory synaptic inputs from host
neurons as shown electrophysiologically;
the presence of such synapses was
confirmed anatomically by electron mi-
croscopy (EM). The authors also demon-
strated the reverse, that host pyramidal
cells received synaptic input from grafted
interneurons. To this end, transplanted
cells had been infected in culture with a
lentivirus that expressed channelrhodop-Cell Stem Cell 15,sin-2 (ChR2); stimulation with blue light
then evoked inhibitory postsynaptic cur-
rents (IPSCs) in endogenous host pyrami-
dal cells. Synapse formation between
grafted interneurons and host neurons
was also confirmed anatomically by EM.
Most importantly, transplanted cells
produced a marked decrease in seizure
frequency and, in a subset of mice, elimi-
nated seizures altogether.
Epilepsy is not a singular disease, but is
instead a collection of various syndromes
with a variety of causes and associated
neuropathology, and it has been difficult
to model many human epilepsy syn-
dromes. The mouse model of acquired
chronic temporal lobe epilepsy (TLE)
induced by the chemoconvulsant pilocar-
pine, used by Cunningham and col-
leagues, is a well validated one. TLE is a
common epilepsy syndrome in children,
adolescents, and adults, and it is the
most common partial onset epilepsy and
the most common cause of intractable
(medication-resistant) epilepsy in the
adult population. While a variety of patho-
logical findings have been found in exper-
imental models of TLE as well as in post-
surgical or postmortem human temporal
lobe specimens from patients with TLE,
a consistent finding is cell loss, including
loss of interneurons in the hilus of the
dentate gyrus. By definition, TLE is also
a focal epilepsy, with seizures emanating
from the temporal lobe, hence injections
of therapeutic cell populations can be tar-
geted to the purported seizure-generating
region.
Some forms of epilepsy are associated
with inflammation, gliosis, and cell death,November 6, 2014 ª2014 Elsevier Inc. 527
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may be partially causative or a contrib-
uting factor to epilepsy pathogenesis.
The logical extension of these findings is
to consider the possibility that replace-
ment of cells that have died during the
epileptogenic process or in the course of
chronic epilepsy might represent a viable
treatment strategy and even a potential
cure.
Cell-based therapies have been
considered for the treatment of epilepsy
for over 2 decades. Strategies have
included the use of fetal brain tissue
from hippocampus, neocortex, and
subcortical structures, mouse and human
neural stem cells, and genetically engi-
neered neurons or glia designed to
express putative anticonvulsant sub-
stances, among others, each with their
specific advantages and challenges for
clinical translation (reviewed in Lo¨scher
et al., 2008, Shetty, 2011; Sebe and Bara-
ban, 2011; Southwell et al., 2014; Tyson
and Anderson, 2014). Maisano and col-
leagues recently showed that MGE-like
cortical interneuron precursors derived
from mouse ESCs could survive and
incorporate into the hippocampi of mice
with pilocarpine-induced TLE (Maisano
et al., 2012); however, no treatment effect
was observed, perhaps because these
cells remained too immature. Investiga-
tors have had greater success in the
treatment of epilepsy using transplanted
fetal MGE precursors. Hunt and col-
leagues used cell transplants derived
from E13.5 mouse MGE to treat epilepsy
in the pilocarpine model, and they
showed dramatic suppression of seizures
as well as normalization of associated
memory impairment seen in epileptic
mice (Hunt et al., 2013). In contrast to
ESC-derived interneuron progenitors,
MGE precursors appeared to develop528 Cell Stem Cell 15, November 6, 2014 ª2into mature cortical interneurons much
faster.
The impact of this study for the stem
cell community is clear: Cunningham
and colleagues have made an important
advance in the successful treatment of
epilepsy in an experimental model using
cortical GABAergic interneuron progeni-
tors derived from ESCs. When we envi-
sion the ultimate application of such cell-
based therapy to human patients, stem
cells offer a number of advantages over
other sources of cells, including the capa-
bility of being genetically modified and of
potentially unlimited expansion in vitro.
In the future, stem cell biologists may be
able to generate cortical interneurons
from induced pluriopotent stem cells
derived from a patient’s own cells.
Future work will be required to under-
stand the exact mechanisms mediating
the anticonvulsant effects of transplanted
interneurons. A clear feature of the study
by Cunningham and colleagues, and
shown previously by other groups (Nicho-
las et al., 2013), is that transplanted ESC-
derived cortical interneuron precursors
exhibit a markedly protracted develop-
mental trajectory. How is it that still imma-
ture interneurons are able to suppress
seizures? Although a reasonable and
perhaps obvious hypothesis, it has yet to
be proven that it is the GABAergic identify
of these cells, let alone enhanced func-
tional GABA-mediated inhibition, that
suppresses seizures in this study and in
a previous study using interneuron pre-
cursors derived from mouse embryonic
MGE (Hunt et al., 2013). When consid-
ering translation of this approach, it is
important to consider how quickly trans-
planted cells would be able to engraft
and suppress epilepsy. For many patients
with severe forms of epilepsy, the months
or even years required for maturation of014 Elsevier Inc.transplanted hESC-derived interneurons
would be too long. Another important
consideration is how long the seizure-
suppressing effect would last. Finally, in
addition to treating already existing epi-
lepsy, can such cells be used to prevent
epilepsy development in at-risk individ-
uals, for instance if delivered immediately
after an epileptogenic brain injury such as
that used by Cunningham et al. (but prior
to the appearance of seizures)? We await
the answers to such questions, because
they may enable the development of
stem-cell-based therapies to treat other
epilepsy syndromes and even perhaps
prevent epilepsy development.
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